587 Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models oleh John Williams, Wilson Guzman, Minjie Zhang, Parker Johnson, Megan McLaughlin, Kurt Jenkins, Caitlin O’Toole, Magali Pederzoli-Ribeil, Margaret Karow, Ronan O’Hagan, Jennifer O’Neil, Ugur Eskiocak, Miso Park, Timothy Clackson